Teva presents real-world data for austedo® (deutetrabenazine) tablets with 4-week patient titration kit at psych congress elevate 2023

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced 12 presentations across its neuroscience portfolio featured at the psych congress elevate 2023 annual meeting taking place on june 1-4, 2023. two presentations feature real-world data for austedo (deutetrabenazine) tablets for adults living with td. data presented will include interim findings from the start trial, a phase 4 s.
TEVA Ratings Summary
TEVA Quant Ranking